The safety and efficacy of bevacizumab in treatment of recurrent low-grade glioma: a systematic review and meta-analysis.

Mohammad Amin Habibi Farhang Rashidi Hossein Gharedaghi Mohammad Reza Arshadi Sana Kazemivand

Published in: European journal of clinical pharmacology (2024)

According to the RANO scale and PFS, clinicians should be aware that Bevacizumab could be a favorable alternative therapy for recurrent LGG. Furthermore, bevacizumab exhibits minimal toxicity and high tolerability in recurrent LGG.

Keyphrases

low grade
metastatic colorectal cancer
high grade
oxidative stress
open label
clinical trial
randomized controlled trial
combination therapy
double blind
placebo controlled